stockrowGinkgo Bioworks Holdings, Inc. (DNA) vs Syndax Pharmaceuticals, Inc. (SNDX)
- Ginkgo Bioworks Holdings, Inc. DNA 9.81 −4.29%
- Syndax Pharmaceuticals, Inc. SNDX 9.69 +1.04%
Ginkgo Bioworks Holdings, Inc. and Syndax Pharmaceuticals, Inc. are both Biotechnology companies. Syndax Pharmaceuticals, Inc. is the larger, with a market value of $863.4M against $679.1M — 1.3× the size. Syndax Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 159.5% against −23.6%. Syndax Pharmaceuticals, Inc. has the higher net margin (−72.4% vs −192.0%) and the higher return on invested capital (−83.4% vs −155.8%). Across the 17 metrics below, Syndax Pharmaceuticals, Inc. leads on 12 and Ginkgo Bioworks Holdings, Inc. on 5.
Valuation
Profitability
| Metric | DNA | SNDX | Biotechnology median |
|---|---|---|---|
| Gross margin | 69.79% | 92.21% | 68.81% |
| Operating margin | (204.50%) | (61.72%) | 0.00% |
| Net margin | (191.99%) | (72.38%) | 0.00% |
| Free cash flow margin | (132.29%) | (61.36%) | 0.00% |
| Return on equity | (52.71%) | (426.43%) | (50.30%) |
| Return on assets | (23.53%) | (33.67%) | (45.47%) |
| Return on invested capital | (155.79%) | (83.42%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack